Cargando…
Multimodal 4-arylchromene derivatives with microtubule-destabilizing, anti-angiogenic, and MYB-inhibitory activities
Aim: Efficient and readily available anticancer drugs are sought as treatment options. For this reason, chromene derivatives were prepared using the one-pot reaction and tested for their anticancer and anti-angiogenic properties. Methods: 2-Amino-3-cyano-4-(aryl)-7-methoxy-4H-chromene compounds (2A-...
Autores principales: | Köhler, Leonhard H. F., Reich, Sebastian, Yusenko, Maria, Klempnauer, Karl-Heinz, Begemann, Gerrit, Schobert, Rainer, Biersack, Bernhard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
OAE Publishing Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099595/ https://www.ncbi.nlm.nih.gov/pubmed/37065868 http://dx.doi.org/10.20517/cdr.2022.90 |
Ejemplares similares
-
Bcr-TMP, a Novel Nanomolar-Active Compound That Exhibits Both MYB- and Microtubule-Inhibitory Activity
por: Yusenko, Maria V., et al.
Publicado: (2021) -
2‐Amino‐4‐aryl‐5‐oxo‐4,5‐dihydropyrano[3,2‐c]chromene‐3‐carbonitriles with Microtubule‐Disruptive, Centrosome‐Declustering, and Antiangiogenic Effects in vitro and in vivo
por: Köhler, Leonhard H. F., et al.
Publicado: (2022) -
A novel cell-based screening assay for small-molecule MYB inhibitors identifies podophyllotoxins teniposide and etoposide as inhibitors of MYB activity
por: Yusenko, Maria, et al.
Publicado: (2018) -
Src-Family Protein Kinase Inhibitors Suppress MYB Activity in a p300-Dependent Manner
por: Biyanee, Abhiruchi, et al.
Publicado: (2022) -
Oncogenic point mutations in the Myb DNA-binding domain alter the DNA-binding properties of Myb at a physiological target gene
por: Ivanova, Olga, et al.
Publicado: (2007)